ZEDENOLEUCEL
UNII L4D9X59F34

Substance Identification & Data

This profile provides standardized clinical and technical data for Zedenoleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L4D9X59F34.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

L4D9X59F34

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ZEDENOLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C175351

National Cancer Institute reference terminology for clinical and research data.

INN ID

11796

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

HI-190

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zedenoleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ZEDENOLEUCEL

Common Names & Synonyms

MULTI-TUMOR-ASSOCIATED ANTIGEN (TAA) SPECIFIC T LYMPHOCYTES. THE MANUFACTURING PROCESS SELECTIVELY AMPLIFIES TUMORTARGETED T CELL PRECURSORS EX VIVO USING ANTIGEN PRESENTING CELLS (APCS) EXPRESSING A RANGE OF TAAS THAT ARE SELECTIVELY OVEREXPRESSED ON LEUKEMIC CELLS. THE STIMULATION IS PERFORMED USING ASEPTIC METHODS AND CLINICAL GRADE PEPTIDE MIXTURES. DONOR T CELLS ARE CULTURED WITH AUTOLOGOUS APCS LOADED WITH THE PEPTIDE MIXTURES SPANNING THE ENTIRE PRIMARY SEQUENCES OF THE FOUR TUMOR ASSOCIATED ANTIGENS PRAME, NY-ESO-1, SURVIVIN, AND WT1 IN THE PRESENCE OF RECOMBINANT CYTOKINES TO STIMULATE T CELL GROWTH

ZEDENOLEUCEL [INN]

ZEDENOLEUCEL [USAN]

Technical Codes

MT-401

External Clinical & Regulatory Resources

Previous UNIIL4D6S34UYZ

Next UNIIL4DMQ5TH5Y